| human | Q5 |
| P9844 | IRIS UNIPV author ID | 10646 |
| P496 | ORCID iD | 0000-0002-7693-4825 |
| P1053 | ResearcherID | K-5741-2016 |
| P1153 | Scopus author ID | 12775670000 |
| P108 | employer | University of Pavia | Q219317 |
| P735 | given name | Francesca | Q2695945 |
| Francesca | Q2695945 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q33718805 | A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis |
| Q43586549 | A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. |
| Q36862339 | A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. |
| Q41505050 | A practical approach to the diagnosis of systemic amyloidoses. |
| Q35006134 | A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli |
| Q64360406 | ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis |
| Q38809423 | Advances in proteomic study of cardiac amyloidosis: progress and potential. |
| Q43984985 | Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. |
| Q33334024 | Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. |
| Q38215594 | Biochemical markers in early diagnosis and management of systemic amyloidoses. |
| Q46163563 | Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. |
| Q46909999 | Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. |
| Q51084760 | Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. |
| Q38062901 | Clinical proteomics for diagnosis and typing of systemic amyloidoses. |
| Q47140242 | Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity |
| Q64071946 | Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient |
| Q53281859 | How do we improve treatments for patients with amyloidosis using proteomics? |
| Q51039671 | Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. |
| Q58030328 | Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine |
| Q37061542 | In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. |
| Q39343666 | Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment. |
| Q58029880 | Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients |
| Q58030190 | Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis |
| Q92168013 | Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations |
| Q53792995 | Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. |
| Q38406601 | Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. |
| Q48615482 | Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. |
| Q37676296 | Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. |
| Q53988051 | Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. |
| Q58424126 | Patterns of relapse after upfront bortezomib therapy in AL amyloidosis |
| Q58289419 | Prognostication of survival and progression to dialysis in AA amyloidosis |
| Q37955712 | Proteomic typing of amyloid deposits in systemic amyloidoses. |
| Q33467519 | Proteomics in protein misfolding diseases. |
| Q49496994 | Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing |
| Q46194651 | Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells |
| Q50526227 | Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. |
| Q58030111 | Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide |
| Q58424130 | Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response |
| Q45740421 | Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. |
| Q92570522 | Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients |
| Q30570936 | Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity |
| Q55167558 | Systemic amyloidoses and proteomics: The state of the art. |
| Q45168852 | The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). |
| Q92167983 | The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis |
| Q87411549 | The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis |
| Q53156031 | Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone. |
| Q58030485 | Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis |
| Q58293086 | Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis |
| Q92388398 | Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration |
Search more.